Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Fineline Cube Jan 20, 2026
Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Fineline Cube Jan 20, 2026
Company Deals

I-Mab Partners with Wuxi Diagnostics to Advance Biomarker-Driven Clinical Studies

Fineline Cube Nov 29, 2022

China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to...

Company Deals

Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round

Fineline Cube Nov 29, 2022

China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...

Company

Alibaba Health Reports 22.9% Revenue Growth in H1 2022

Fineline Cube Nov 29, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the...

Company Deals

3D Medicines Set for IPO in Hong Kong, Aiming to Raise Up to USD 55 Million

Fineline Cube Nov 29, 2022

China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO)...

Company Policy / Regulatory

China’s Medical Product Trade Surplus Declines Amid COVID-19 Impact

Fineline Cube Nov 28, 2022

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Deals

Nuance Pharma Partners with DKSH to Launch Bentrio Nasal Spray in Hong Kong and Macau

Fineline Cube Nov 28, 2022

China-based Nuance Pharma has announced a partnership with DKSH Hong Kong Business Unit Healthcare to...

Deals

Biocytogen and ADC Therapeutics Enter Evaluation and Option Agreement

Fineline Cube Nov 28, 2022

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss...

Company Drug

Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC

Fineline Cube Nov 28, 2022

Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized...

Company Deals

ZSHK Laboratories Raises RMB 100 Million in Series B Financing Round

Fineline Cube Nov 28, 2022

China-based pre-clinical Contract Research Organization (CRO) ZSHK Laboratories Limited has reportedly raised close to RMB...

Company

Ascentage Pharma Receives Drug Production License for Suzhou Plant

Fineline Cube Nov 28, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following...

Company Drug

Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea

Fineline Cube Nov 28, 2022

China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan...

Company

Taizhou-Wuxi-Lianyungang Biomedicine Hub Launched at China Medical Expo

Fineline Cube Nov 28, 2022

The 13th China (Taizhou) International Medical Expo witnessed the launch of the Taizhou-Wuxi-Lianyungang national biomedicine...

Company Deals

Huadong Medicine Partners with Dongyang Med for Equity Collaboration

Fineline Cube Nov 28, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced an equity collaboration deal with Zhejiang...

Company Drug

Jiangsu Hengrui Gets NMPA Approval for HR20031 Clinical Study in Type 2 Diabetes

Fineline Cube Nov 28, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products...

Drug

Fosun Pharma’s Henlius Completes Clinical Trial Filing for HLX301 in Australia

Fineline Cube Nov 25, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary,...

Company Medical Device

Peijia Medical Announces First Patient Implant in MonarQ TTVR System Clinical Study

Fineline Cube Nov 25, 2022

China’s Peijia Medical Limited (HKG: 9996) has announced the first patient implant in a global...

Company Deals

Zhejiang Dian Diagnostics Partners with Chengdu Eastern New Area for IVD Hub

Fineline Cube Nov 25, 2022

China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has announced a strategic partnership with Chengdu...

Company Deals

Anyeep Raises RMB 100 Million in Series A Financing for Mass Spectrometry Development

Fineline Cube Nov 25, 2022

Anyeep, a Suzhou-based developer of mass spectrometers, has reportedly raised close to RMB 100 million...

Company Deals

Shanghai Henlius Biotech to Provide R&D Services for COVID-19 Therapy Azvudine

Fineline Cube Nov 25, 2022

China-based Shanghai Henlius Biotech (HKG: 2696) has entered into an agreement to provide clinical study...

Company Drug

China Resources Double-Crane Gains Approval for Definity in China

Fineline Cube Nov 25, 2022

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving market approval from the...

Posts pagination

1 … 540 541 542 … 611

Recent updates

  • Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal
  • Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study
  • AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly
  • Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
  • Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.